Our study provides novel insights into how myeloid-specific Tet2 deficiency exacerbates liver fibrosis through the Ccl2/Ccl8–pMDMs–IL-6–HSCs axis, offering a potential therapeutic avenue for targeting fibrosis in populations with abundant aging individuals with TET2 mutations. This evidence concerns the gene TET2 and Hepatic fibrosis.